- Home
- KNF vs AXSM Comparison
KNF vs AXSM Comparison
Compare KNF & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNF | AXSM |
|---|---|---|
| Founded | 1917 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 10.4B |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KNF | AXSM |
|---|---|---|
| Price | $53.41 | $195.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 17 |
| Target Price | $97.25 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 922.0K | 508.4K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,146,012,000.00 | N/A |
| Revenue This Year | $8.93 | $57.24 |
| Revenue Next Year | $5.28 | $55.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.52 | N/A |
| 52 Week Low | $50.67 | $115.72 |
| 52 Week High | $96.28 | $260.19 |
Technical Indicators
Market Signals| Indicator | KNF | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 32.06 | 35.27 |
| Support Level | N/A | $179.00 |
| Resistance Level | $80.57 | $225.16 |
| Average True Range (ATR) | 2.07 | 8.10 |
| MACD | -0.06 | -1.31 |
| Stochastic Oscillator | 25.20 | 7.27 |
Price Performance
Historical ComparisonAbout KNF Knife Riv Holding Co.
Knife River Corp is a people-first construction materials and contracting services company. It provides construction materials and contracting services to build safe roads, bridges, airport runways, and other critical infrastructure needs that connect people. The group is a provider of crushed stone, sand, and gravel in the United States. It operates through four reportable segments: West, Mountain, Central, and Energy Services.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.